Ask AI
ProCE Banner Activity

Assessment, Diagnosis, and Treatment of Tardive Dyskinesia in Elders

Clinical Thought

Read this commentary about how the increased use of dopamine-blocking medications such as antipsychotics across a wide range of indications makes detection and treatment of tardive dyskinesia even more important to maintain patient quality of life into old age.

Released: December 30, 2025

Share

Provided by

ProCE Banner

Supporters

Supported by an educational grant from Neurocrine Biosciences.

Neurocrine Biosciences

Target Audience

This educational activity is intended for psychiatrists, geriatricians, nurse practitioners, physician associates, general and family practice physicians, pharmacists, psychologists, social workers, and other healthcare professionals who treat patients or advise HCP care teams regarding their patients with tardive dyskinesia who may benefit from this education. Target audiences for specific satellite symposia are adjusted as appropriate for each conference.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify risk factors for TD that increase susceptibility in older individuals​

  • Implement best practices for using screening and assessment tools with patients at risk for TD

  • Interpret screening tool results to identify TD, considering patient and caregiver reports

  • Evaluate the safety, effectiveness, and pharmacologic properties of VMAT2 inhibitors for managing TD in older adults and special populations

  • Develop an individualized treatment plan for diverse patient populations with TD

Disclosure

Primary Author

Susan Scanland, MSN, CRNP, GNP-BC, CDP

CEO & Founder
Dementia Connection LLC
Clarks Summit, Pennsylvania

Susan Scanland, MSN, CRNP, GNP-BC, CDP: consultant/advisor/speaker: Acadia, Axsome, BioXcel, Eisai, Lundbeck, Otsuka, Teva.